SecBot SecBot
PRESS-RELEASE ·Filed Jun 9, 2026

IVVD

Invivyd
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

No efficacy or safety data released, stock reaction likely muted until Q3 2026 topline readouts. Monitor DECLARATION and LIBERTY data for VYD2311's differentiation vs. mRNA vaccines on tolerability.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9900
T+0 close · Jun 9, 2026 · via day close
Latest settled
−18.79%
T+60 · $0.8040
Vs SPY
−22.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 9 $0.9900entry
  2. T+1 · 5mo ago −9.00%α −7.42% · $0.9009
  3. T+5 · 5mo ago −12.26%α −14.67% · $0.8686
  4. T+20 · 4mo ago −4.87%α −6.32% · $0.9418
  5. T+60 · 3mo ago −18.79%α −22.60% · $0.8040
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Invivyd dosed first participants in the LIBERTY Phase 3 trial evaluating VYD2311 (mAb) vs. mRNA COVID-19 vaccine, with topline data expected Q3 2026 alongside pivotal DECLARATION trial results. This is an early-stage clinical milestone with no efficacy or safety data yet, a routine pipeline update for a pre-revenue biotech.

Key Facts

  • First participants dosed in LIBERTY Phase 3 trial (N≈210) comparing VYD2311 alone, mRNA vaccine alone, and co-administration.
  • Topline data expected Q3 2026, concurrent with pivotal DECLARATION trial data.
  • Primary endpoints are safety/tolerability through Day 6 (TEAEs, injection site reactions, systemic symptoms).
  • LIBERTY is part of the broader REVOLUTION program aiming to position VYD2311 as a preferred COVID-19 prevention option over mRNA vaccines.
  • VYD2311 shares antibody backbone with pemivibart (EUA for immunocompromised PrEP) and adintrevimab.

Financial Impact

No financial data disclosed; pre-revenue clinical-stage biotech.

Risk Factors

  • Clinical trial failure or underwhelming safety/tolerability data vs. mRNA vaccines.
  • Regulatory hurdles for BLA submission; reliance on EUA for pemivibart may not translate to VYD2311 approval.
  • Viral evolution could reduce VYD2311 neutralizing activity against emerging variants.
  • Enrollment delays or slower-than-expected recruitment could push Q3 2026 timeline.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3308710

Track record

19 reports on IVVD

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
  2. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
  3. Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
  5. Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
  6. Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
  7. Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
  8. Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
  10. Jun 9, 202622w ago Press Release Neutral 4/10 Viewing Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 9, 2026